Question · from the living review of Targeted Therapy Lung Cancer →

Is it true that dabrafenib plus trametinib (BRAF-MEK inhibitor combination) achieves clinically meaningful ORR (>60%) in BRAF V600E-mutant NSCLC with durable responses?

Likely updated weekly · as of

Priors rates this Likely — 79 out of 100, updated weekly. Probably — but it is not fully settled. On the claim that dabrafenib plus trametinib (BRAF-MEK inhibitor combination) achieves clinically meaningful ORR (>60%) in BRAF V600E-mutant NSCLC with durable responses, its four-agent AI review panel weighs 8 primary peer-reviewed studies.

RefutedDoubtfulUncertainLikelyEstablished
where this sits on Priors’ scale of how settled the evidence is

How we got this answer. Priors runs each claim through a panel of four AI agents, each acting as a specialist expert reviewer. They read the published, peer-reviewed studies behind the question, judge how strong, consistent and reliable the evidence is, and turn that judgment into a single rating from 0 to 100 — refreshed every week as new studies appear, so it reflects where the evidence stands today, not a one-off verdict.

The traceable studies behind this rating — and the panel’s single strongest counter-argument to it — are in Priors’ full Targeted Therapy Lung Cancer review.

Related Oncology — solid tumours questions

Is it true that alectinib is superior to crizotinib as first-line treatment for ALK-positive advanced NSCLC, with significantly improved PFS and superior CNS efficacy? → Is it true that osimertinib (third-generation EGFR TKI) is superior to first- and second-generation EGFR TKIs as first-line treatment for EGFR-mutant (exon 19 deletion or L858R) advanced NSCLC, with improved PFS, OS, and CNS efficacy? → Is it true that adjuvant osimertinib significantly improves disease-free survival and overall survival in patients with resected EGFR-mutant NSCLC (stage IB-IIIA)? → Is it true that lorlatinib (third-generation ALK/ROS1 TKI) demonstrates superior progression-free survival and CNS activity in ALK-positive NSCLC in the first-line setting, with the lowest intracranial progression rate of any ALK inhibitor? →
Reflects the peer-reviewed evidence as of 17 July 2026 and updates as new studies land. AI can make mistakes. Not medical advice.